Leukemia Clinical Trial
Official title:
Phase II Study of the Efficacy of rH Interleukin-2 in Patients With Slowly Progressing Acute Myelogenous Leukemia (AML) and With Limited Bone Marrow Blastosis After Autologous Stem Cell Transplantation or Chemotherapy
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill acute
myelogenous leukemia cells.
PURPOSE: Phase II trial to study the effectiveness of interleukin-2 in treating patients
with acute myelogenous leukemia that has relapsed following previous treatment.
OBJECTIVES: I. Assess the therapeutic activity of interleukin-2 (IL-2) in patients with
slowly progressing acute myeloid leukemia with limited bone marrow blastosis either in first
relapse after autologous bone marrow or peripheral blood stem cell transplantation, or with
more advanced disease (i.e., refractory to chemotherapy regimens). II. Characterize the
acute side effects of IL-2 in these patients.
OUTLINE: This is an open label, nonrandomized, multicenter study. Patients are stratified
into two categories of prior failed treatments (first relapse after autologous bone marrow
or peripheral blood stem cell transplantation vs first or subsequent relapse either
refractory to or not eligible for further conventional treatment). Interleukin-2 (IL-2) is
administered as a continuous intravenous infusion on 5 consecutive days at daily escalating
doses for the first cycle. When the individual maximum tolerated dose (MTD) has been
determined, 3 more cycles are given at the MTD. There are 3 days of rest between each
treatment cycle. After the induction phase, maintenance cycles of IL-2 are administered
starting 4 weeks after the last induction treatment. Maintenance cycles of IL-2 are
administered subcutaneously on 5 consecutive days every 4 weeks for 2 years, and
subsequently every other month for a maximum of 3 years. Treatment continues until disease
progression or unacceptable toxicity for a maximum of 5 years. Patients are followed every 4
weeks during the first 2 years, then every 8 weeks during the next 3 years or until
documented progression, and then every 3 months until death.
PROJECTED ACCRUAL: A maximum of 86 (57 transplanted; 29 patients nontransplanted) patients
will be accrued into this study within 2 years.
;
Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A |